Last Updated on October 16, 2021 by The Health Master
Further, SOTAX Group and Ortiv-Q3 had announced their collaboration, in order to strengthen their capabilities in the field of pharma services, a statement from SOTAX informed.
It said that the inauguration took place in the presence of the Guest of Honour Rolf Benz, CEO and President of the Board, SOTAX Group.
According to the statement, the laboratory facility is spread over ten thousand sq.ft. and is a new, state-of-the-art infrastructure including modern workspace and the set of latest instruments to perform cGMP analytical services with a clear focus on complex dosage forms characterisation.
The new infrastructure will facilitate accelerating complex formulation development programme of global clients and shall work with a high throughput to perform excellent services to customers. Soon, the lab will be accredited by various regulatory agencies.
The new lab will offer various Routine Analytical Services (GMP) for QC and stability studies, clinical and commercial batch release and R&D services like In-Vitro Release Testing (IVRT, USP type 1-7), IVPT, Reverse Engineering, Q3 characterisation (physico-chemical), API screening and impurities characterisation.
It would also support services like troubleshooting and investigations, training, consulting, audits, support for Q1/Q2 regulatory clearance, etc, added the statement.